Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VYNE Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate, Sales $202.00K Beat $50.00K Estimate

Author: Benzinga Newsdesk | May 08, 2025 08:06am
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $202.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 304.00 percent. This is a 106.12 percent increase over sales of $98.00 thousand the same period last year.

Posted In: VYNE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist